Halozyme Therapeutics (HALO)
News
| May 27 | http://stks.co/401H follow the smart $$. RJ Kirk own 9.3mil shrs of $HALO & lately a consistent buyer. On last deal he became billionaire! by mccartjt |
| May 25 | 10 Stocks Favored By Hedge Funds And Company Insiders |
| May 23 | http://stks.co/3xM6 Mentions $HALO & $ANGI I'll go with the billionaire RJ Kirk.. Looks like a safe bet to me by mccartjt |
| May 23 | 5 Stocks Insiders Love Right Now |
| May 23 | Today’s Watchlist for SHORT Stocks: $FONR; $VELT; $GDP; $REE; $HALO by RalfKaiser |
| May 21 | @TradeIdeasQuant $halo believe it was insider buying that brought it to attention last wk & thanks to a twit found here = reason i'm in. by Good2go |
| May 21 | $HALO Mentioned more than normal on StockTwits - Currently at 13 x average daily social activity by TradeIdeasQuant |
| May 21 | picked up $halo & $lvs they r set 2 $win (which i'm in too) holding $bas & $royl good day thanks 2 $spy retrace. by Good2go |
| May 21 | RT @bradloncar some how I don't think that a billionaire is the sucker in the room! LOL $HALO by mccartjt |
| May 21 | @mccartjt Sometimes there is no better medicine for a stock than a well-placed insider buy. $HALO by bradloncar |
| May 20 | Insider Buys And Sells: Netflix Buys And NVR Sales |
| May 20 | Insider Buying Trends: Are These Cash-Rich Companies Ready For A Rally? |
| May 19 | Noteworthy Insider Buys Last Week In 2 Beaten Down Biotechs, With 4 Other Buys And Se... |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes that either transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefit. The company's products targeting the area outside the cell known as the extracellular matrix, or Matrix. The company has partnership with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc., or Roche, to apply Enhanze Technology to Roche's biological therapeutic compounds for up to eight targets; and with Baxter Healthcare Corporation to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. Halozyme Therapeutics, Inc. was founded by Gregory Ian Frost in 1998 and is based in San Diego, California.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Halozyme Therapeutics is up 21.58% over the last year vs S&P 500 Total Return up 1.18%, Medivation up 263.2%, and QLT up 3.13%.
- HALO Total Returns
- ^SPXTR Total Returns
- MDVN Total Returns
- QLTI Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these HALO related companies
Pro Strategies Featuring HALO
Did Halozyme Therapeutics make it into our Pro Portfolio Strategies?
HALO Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other HALO Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HALO | 8.17 | -0.14 | -1.68% | 931.47M |
| HALL | 7.21 | -0.07 | -0.96% | 140.21M |
| IIIN | 9.78 | +0.00 | +0.00% | 172.23M |
| III | 1.30 | +0.03 | +2.36% | 46.13M |
| IIF | 14.64 | +0.19 | +1.31% | |
| IIC | 15.87 | +0.05 | +0.32% | |
| IHT | 2.03 | +0.00 | +0.00% | 17.19M |
| IHS | 101.70 | -0.32 | -0.31% | 6.650B |
| ICGE | 8.82 | +0.03 | +0.34% | 329.98M |
| ICFI | 22.51 | +0.15 | +0.67% | 442.73M |
